Quest Diagnostics (NYSE:DGX) is set to issue its quarterly earnings data before the market opens on Tuesday, October 23rd. Analysts expect the company to announce earnings of $1.68 per share for the quarter.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Tuesday, July 24th. The medical research company reported $1.75 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.01). Quest Diagnostics had a net margin of 10.56% and a return on equity of 15.45%. The business had revenue of $1.92 billion during the quarter, compared to analysts’ expectations of $1.95 billion. During the same period in the previous year, the company posted $1.55 earnings per share. Quest Diagnostics’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

NYSE:DGX opened at $102.50 on Monday. Quest Diagnostics has a one year low of $90.31 and a one year high of $116.49. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.05 and a current ratio of 1.12. The firm has a market capitalization of $14.01 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 1.95 and a beta of 0.73.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 22nd. Shareholders of record on Friday, October 5th will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.95%. The ex-dividend date is Thursday, October 4th. Quest Diagnostics’s payout ratio is 37.04%.

DGX has been the topic of several recent research reports. Barclays raised shares of Quest Diagnostics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $120.00 to $130.00 in a report on Monday, June 25th. Deutsche Bank lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating and set a $108.00 price target on the stock. in a report on Wednesday, June 27th. MED lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, June 27th. Evercore ISI raised shares of Quest Diagnostics from an “in-line” rating to an “outperform” rating and set a $103.00 target price on the stock in a research note on Tuesday, July 10th. Finally, Argus set a $120.00 target price on shares of Quest Diagnostics and gave the stock a “buy” rating in a research note on Friday, September 14th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Quest Diagnostics has an average rating of “Buy” and an average target price of $114.77.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company's Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, gene-based and esoteric testing, anatomic pathology, and other diagnostic information services.

Recommended Story: Trading Penny Stocks

Earnings History for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.